Scott Morenstein

Scott Morenstein is currently a Managing Director in Blackstone Multi-Asset Investing (BXMA), a position he has held since joining Blackstone in 2022.2 Prior to this, he served as Managing Director at CAM Capital from November 2013 to 2022, where he led biotechnology investing.12

Morenstein's career in finance and healthcare spans over two decades. His previous roles include:

• Managing Director at Valence Advantage Life Sciences Fund (January 2012 - November 2013)2
• Principal at Caxton Advantage Venture Partners (2007 - 2011)2
• Investment Banking Associate and founding member of Seaview Securities (2003 - 2005)2
• Healthcare Investment Banker and Equity Research Analyst at Lehman Brothers (2000 - 2002)2

He has served on the boards of several biopharmaceutical companies, including:

• Molecular Templates, Inc. (Nasdaq: MTEM) since July 20171
• Antios Therapeutics since November 20181
• Primmune Therapeutics since March 20201
• Avenge Bio since December 20211

Morenstein holds an M.B.A. from Harvard Business School and a B.A. from the University of Pennsylvania with a degree in the Biological Basis of Behavior.12